News | May 24, 2025
Strides Pharma Q4 net profit rises 5x to Rs. 113 Cr
For the full year FY25, net profit soared 12x to Rs 345 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
Dr. Muthu was last associated with Mankind Pharma
Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Subscribe To Our Newsletter & Stay Updated
